Ocimum Biosolutions of Indianapolis, Ind., has received US Patent No. 7,415,358, “Molecular toxicology modeling.” The patent claims a method for determining whether a test compound is a renal toxin by: a) exposing kidney tissue or kidney cells to the test compound; b) preparing a normalized gene expression profile of at least ten genes for said kidney tissue or kidney cells by hybridization of nucleic acids to a microarray; c) comparing the gene expression profile to a renal toxicity model; and d) scoring the comparison to determine whether the test compound is a renal toxin.
Samsung Electronics of Seoul, Korea, has received US Patent No. 7,416,705, “Spotting device for manufacturing DNA microarray and spotting method using the same.” The patent claims a spotting device for dropping and immobilizing a solution of biomolecules, for example nucleic acids and proteins, on a microarray surface to manufacture a DNA microarray. The device includes: a) a first microchannel with a tube shape; b) a supplying unit supplying the solution of biomolecules to the first microchannel; c) a biomolecule solution droplet forming unit cross-linked to the first microchannel and forming biomolecule solution droplets with a predetermined size by periodically jetting a gas toward the biomolecule solution flowing in the first microchannel; d) a second microchannel linked to the first microchannel having a greater diameter than the first microchannel; e) a cooling unit surrounding at least a part of the second microchannel to freeze the biomolecule solution droplets which pass through the second microchannel; and f) a spotting unit thawing the frozen biomolecule solution droplets and dropping the thawed biomolecule solution droplets on a surface of the DNA microarray. The spotting device can form spots with uniform shape, minimize an effect of temperature on biomolecules, and easily manipulate biomolecules when manufacturing a DNA microarray, the patent states.
Oscient Pharmaceuticals of Waltham, Mass., and Wyeth of Madison, NJ, have received US Patent No. 7,416,849, “HBM variants that modulate bone mass and lipid levels.” The patent claims methods and materials used to express an HBM-like polypeptide derived from HBM, LRP5 or LRP6 in animal cells and transgenic animals. The invention provides nucleic acids, including coding sequences, oligonucleotide primers and probes, proteins, cloning vectors, expression vectors, transformed hosts, methods of developing pharmaceutical compositions, methods of identifying molecules involved in bone development, and methods of diagnosing and treating diseases involved in bone development and lipid modulation. In one embodiment, the invention is directed to methods for treating, diagnosing and preventing osteoporosis.
Micronas of Freiburg, Germany, has received US Patent No. 7,416,901, “Method and coating apparatus for the manufacture of a microarray.” The patent describes a method for the manufacture of a microarray, where surface areas of a chip are brought into contact with different aqueous solutions that contain at least one coating substance. For each of the individual surface areas, an absorbent substrate is provided and is filled with the solution that is to be brought into contact with the surface area in question during the manufacturing process.
LG Life Sciences of Seoul, Korea,has received US Patent No. 7,417,138, “PNA chip for determining genotypes of mycobacterial species using plastic substrate coated with epoxy group-containing polymer and method of determining genotypes of mycobacterial species using the PNA chip.” The patent claims a peptide nucleic acid chip for determining the genotypes of mycobacterial species in which probe PNAs are immobilized on a plastic substrate coated with an epoxy group-containing polymer. The patent also claims a method of determining the genotypes of mycobacterial species using the PNA chip. Using the chip and methodology, the genotypes of mycobacterial species known to cause tuberculosis and respiratory diseases can be determined within a short amount of time, the patent states.
Rosetta Inpharmatics of Seattle has received US Patent No. 7,418,351, “Methods for analysis of measurement errors in measured signals.” The patent claims methods for analyzing measurement errors in measured signals obtained in a microarray gene expression experiment. In particular, the patent provides a method for transforming measured signals into a domain in which the measurement errors in the transformed signals are normalized by errors as determined from an error model. The patent claims the methods are useful for analyzing measurement errors in signals in which at least portion of the error is dependent on the magnitudes of the signals. Such transformed signals permit analysis of data using traditional statistical methods, such as ANOVA and regression analysis. Magnitude-independent errors can also be used for comparing level of measurement errors in signals of different magnitudes.
PamGene of Den Bosch, the Netherlands, has received US Patent No. 7,419,778, “Method for high throughput cell-based assays using versatile living microarrays.” The patent claims methods for screening of cellular responses of cellular components by: a) providing cellular components on the surface of a substrate containing an array of detector molecules; b) delivering test compounds to positions on the substrate corresponding to the arrayed detector molecules on the surface of the solid substrate; c) incubating the test compounds with cellular components on the surface of the solid support, under conditions allowing the induction of cellular responses; d) assaying the cellular responses; and, e) identifying and characterizing the cellular responses induced by the test compounds. The patent also claims microarrays and kits for carrying out the described methods.